These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34773311)

  • 21. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary care provider perspectives on and utilization of a mandatory prescription drug monitoring program in New York City.
    Harocopos A; Allen B; Chernick R
    Fam Pract; 2022 Mar; 39(2):264-268. PubMed ID: 34268573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Are Real-time Opioid Prescribing Cognitions by Emergency Providers Influenced by Reviewing the State Prescription Drug Monitoring Program?
    Landau A; Lynch M; Callaway C; Suffoletto B
    Pain Med; 2019 May; 20(5):955-960. PubMed ID: 29762757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Provider Compliance With Kentucky's Prescription Drug Monitoring Program's Mandate To Query Patient Opioid History.
    Carey CM; Meille G; Buchmueller TC
    Health Aff (Millwood); 2021 Mar; 40(3):461-468. PubMed ID: 33646863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interstate data sharing of prescription drug monitoring programs and associated opioid prescriptions among patients with non-cancer chronic pain.
    Lin HC; Wang Z; Simoni-Wastila L; Boyd C; Buu A
    Prev Med; 2019 Jan; 118():59-65. PubMed ID: 30316875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid Prescribing After Implementation of Single Click Access to a State Prescription Drug Monitoring Program Database in a Health System's Electronic Health Record.
    Weiner SG; Kobayashi K; Reynolds J; Chan K; Kelly R; Wakeman S; Reddy P; Young LD
    Pain Med; 2021 Oct; 22(10):2218-2223. PubMed ID: 33561288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription drug monitoring program policy reform: human and veterinary practitioner prescribing in West Virginia, 2008-2020.
    Hendricks B; Rudisill T; Pesarsick J; Wen S; Dotson T; Wood N; Smith GS
    J Public Health Policy; 2021 Jun; 42(2):249-257. PubMed ID: 33580195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease in Urologic Discharge Opioid Prescribing after Mandatory Query of Statewide Prescription Drug Monitoring Program.
    Myrga JM; Macleod LC; Bandari J; Jacobs BL; Davies BJ
    Urology; 2020 May; 139():84-89. PubMed ID: 32061826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.
    Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F
    Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012.
    Perrone J; DeRoos FJ; Nelson LS
    J Med Toxicol; 2012 Dec; 8(4):341-52. PubMed ID: 22895794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Prescription Drug Monitoring Programs With Opioid Prescribing and Overdose in Adolescents and Young Adults.
    Toce MS; Michelson KA; Hudgins JD; Hadland SE; Olson KL; Monuteaux MC; Bourgeois FT
    Ann Emerg Med; 2023 Apr; 81(4):429-437. PubMed ID: 36669914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Experimental Test of the Effectiveness of Unsolicited Reporting by a Prescription Drug Monitoring Program in Reducing Inappropriate Acquisition of Opioids.
    McDonald DC; Carlson KE; Jalbert SK
    Pain Med; 2019 May; 20(5):944-954. PubMed ID: 29868715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid Prescribing Laws Are Not Associated with Short-term Declines in Prescription Opioid Distribution.
    Davis CS; Piper BJ; Gertner AK; Rotter JS
    Pain Med; 2020 Mar; 21(3):532-537. PubMed ID: 31365095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians.
    Irvine JM; Hallvik SE; Hildebran C; Marino M; Beran T; Deyo RA
    J Pain; 2014 Jul; 15(7):747-55. PubMed ID: 24787089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs?
    Smith RJ; Kilaru AS; Perrone J; Paciotti B; Barg FK; Gadsden SM; Meisel ZF
    Pain Med; 2015 Jun; 16(6):1122-31. PubMed ID: 25688454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of automatic physician review of prescription drug monitoring program data on opioid prescribing in a Maryland statewide hospital system.
    Stryckman B; Schoenbaum A; Klein J; Chasm R; Onukwugha E; Dezman ZD
    J Opioid Manag; 2022; 18(6):547-556. PubMed ID: 36523206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Systematic Review of Interventions and Programs Targeting Appropriate Prescribing of Opioids.
    Moride Y; Lemieux-Uresandi D; Castillon G; de Moura CS; Pilote L; Faure M; Bernartsky S
    Pain Physician; 2019 May; 22(3):229-240. PubMed ID: 31151331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review.
    Mauri AI; Townsend TN; Haffajee RL
    Milbank Q; 2020 Mar; 98(1):57-105. PubMed ID: 31800142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.